Overview

Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Patients With Unresectable or Metastatic Cancer

Status:
Active, not recruiting

Trial end date:
2020-11-15

Target enrollment:

Participant gender:

Summary

This is an open-labeled, single-center, Phase I study to evaluate the safety, tolerability, and efficacy of apatinib (also known as rivoceranib) with nivolumab treatment in patients with unresectable or metastatic cancer. Approximately 12-18 subjects in Phase I dose escalation phase and up to 20 additional subjects in Part II expansion phase. Total study duration will be approximately 18 months: 12 months of recruitment plus 6 months of treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Elevar Therapeutics

Treatments:

Apatinib
Nivolumab